NCT06189040View on ClinicalTrials.gov

Immunogenicity After COVID-19 Vaccines in Adapted Schedules

PHASE4CompletedINTERVENTIONAL
Enrollment

580

Participants

Timeline

Start Date

May 26, 2021

Primary Completion Date

November 3, 2021

Study Completion Date

July 8, 2022

Conditions
Coronavirus Disease 2019COVID-19
Interventions
DRUG

BNT162b2 30µg

intramuscular administration of 30µg

DRUG

BNT162b2 20µg

intramuscular administration of 20µg

DRUG

BNT162b2 6µg

intradermal administration of 6µg

DRUG

mRNA-1273 100µg

intramuscular administration of 100µg

DRUG

mRNA-1273 50µg

intramuscular administration of 50µg

DRUG

ChAdOx1-S [Recombinant]

intramuscular administration of not less than 2.5 x 10\^8 infectious units

Trial Locations (4)

1070

Hôpital Erasme, Brussels

2000

Institute of Tropical Medicine (ITM), Antwerp

2650

Centre for the Evaluation of Vaccination (CEV), Edegem

9000

Centre for Vaccinology (CEVAC), Ghent

All Listed Sponsors
lead

Universiteit Antwerpen

OTHER